Frontier Medicines Announces the Recruitment of Andrew Krivoshik, MD, PhD, as Chief Medical Officer

Based in Boston and South San Francisco, precision medicine focused Frontier Medicines, appointed Andy Krivoshik, MD, PhD, to serve as Chief Medical Officer. As Frontier begins its transition into a clinical stage entity focused on generating medicines against disease-causing proteins previously considered undruggable, Dr. Krivoshik will startup, build and lead the drug development team. He brings two decades of experience in global clinical development, biomarker strategy, translational medicine, product and patient safety, and medical affairs. Prior to Frontier, Dr. Krivoshik served as the president and head of development at Astellas. At Astellas, he managed all global clinical development activities and global functions. His team was responsible for the design and implementation of clinical studies aimed at new or improved products, and he was accountable for the clinical development and regulatory submissions of new medicines including enzalutamide, gilteritinib, roxadustat, enfortumab vedotin, fezolinitant, and zolbetuxumab.

Dr. Krivoshik holds an MD from the University of Illinois College of Medicine at Urbana-Champaign, a PhD in biophysics and computational biology from the University of Illinois at Urbana-Champaign and a BSE in electrical engineering from Princeton University. He received his clinical internship and residency training in pediatric and adolescent medicine at Mayo Clinic, and clinical pediatric hematology and oncology fellowship training at Duke University. He is licensed in multiple jurisdictions as both a physician and professional engineer.